MacroGenics Inc (MGNX) stock
MGNXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.97−0.08 (-3.90%)
Close on Nov 18, 2026Market cap $125.49MP/E –Yield –
MacroGenics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
MacroGenics's operating income for the twelve months ending Jun 30, 2026 was -$40.75M. For fiscal 2025 it was -$72.84M. The highest annual figure on record is $8.21M in fiscal 2012.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$72.84M | – |
| FY2024 | Dec 31, 2024 | -$110.58M | – |
| FY2023 | Dec 31, 2023 | -$168.24M | – |
| FY2022 | Dec 31, 2022 | -$121.42M | – |
| FY2021 | Dec 31, 2021 | -$202.80M | – |
| FY2020 | Dec 31, 2020 | -$131.06M | – |
| FY2019 | Dec 31, 2019 | -$177.19M | – |
| FY2018 | Dec 31, 2018 | -$171.21M | – |
| FY2017 | Dec 31, 2017 | -$22.14M | – |
| FY2016 | Dec 31, 2016 | -$60.04M | – |
| FY2015 | Dec 31, 2015 | -$20.18M | – |
| FY2014 | Dec 31, 2014 | -$38.32M | -10568.6% |
| FY2013 | Dec 31, 2013 | $366.00K | -95.5% |
| FY2012 | Dec 31, 2012 | $8.21M | +56.3% |
| FY2011 | Dec 31, 2011 | $5.25M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$13.85M | – |
| Q1 FY2026 | Mar 31, 2026 | -$33.44M | – |
| Q4 FY2025 | Dec 31, 2025 | -$12.10M | – |
| Q3 FY2025 | Sep 30, 2025 | $18.64M | -65.6% |
| Q2 FY2025 | Jun 30, 2025 | -$43.22M | – |
| Q1 FY2025 | Mar 31, 2025 | -$42.62M | – |
| Q4 FY2024 | Dec 31, 2024 | -$52.84M | – |
| Q3 FY2024 | Sep 30, 2024 | $54.19M | – |
| Q2 FY2024 | Jun 30, 2024 | -$58.18M | – |
| Q1 FY2024 | Mar 31, 2024 | -$53.75M | – |
| Q4 FY2023 | Dec 31, 2023 | -$49.35M | -511.9% |
| Q3 FY2023 | Sep 30, 2023 | -$35.50M | – |
| Q2 FY2023 | Jun 30, 2023 | -$44.96M | – |
| Q1 FY2023 | Mar 31, 2023 | -$38.43M | – |
| Q4 FY2022 | Dec 31, 2022 | $11.98M | – |
| Q3 FY2022 | Sep 30, 2022 | -$24.96M | – |
| Q2 FY2022 | Jun 30, 2022 | -$41.81M | – |
| Q1 FY2022 | Mar 31, 2022 | -$66.64M | – |
| Q4 FY2021 | Dec 31, 2021 | -$58.24M | – |
| Q3 FY2021 | Sep 30, 2021 | -$52.99M | – |
| Q2 FY2021 | Jun 30, 2021 | -$40.28M | – |
| Q1 FY2021 | Mar 31, 2021 | -$51.29M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.17M | – |
| Q3 FY2020 | Sep 30, 2020 | -$36.14M | – |
| Q2 FY2020 | Jun 30, 2020 | -$47.31M | – |
| Q1 FY2020 | Mar 31, 2020 | -$45.45M | – |
| Q4 FY2019 | Dec 31, 2019 | -$38.66M | – |
| Q3 FY2019 | Sep 30, 2019 | -$37.94M | – |
| Q2 FY2019 | Jun 30, 2019 | -$52.97M | – |
| Q1 FY2019 | Mar 31, 2019 | -$47.62M | – |
| Q4 FY2018 | Dec 31, 2018 | -$41.68M | -139.7% |
| Q3 FY2018 | Sep 30, 2018 | -$35.00M | – |
| Q2 FY2018 | Jun 30, 2018 | -$44.31M | – |
| Q1 FY2018 | Mar 31, 2018 | -$50.21M | – |
| Q4 FY2017 | Dec 31, 2017 | $104.97M | – |
| Q3 FY2017 | Sep 30, 2017 | -$47.72M | – |
| Q2 FY2017 | Jun 30, 2017 | -$41.18M | – |
| Q1 FY2017 | Mar 31, 2017 | -$38.21M | – |
| Q4 FY2016 | Dec 31, 2016 | -$35.24M | – |
| Q3 FY2016 | Sep 30, 2016 | -$34.27M | – |
See a number that looks wrong?